Squamous Cell Carcinoma of the Neck with Occult Primary: Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Squamous cell carcinoma of the neck with occult primary (also termed cancer of unknown primary, CUP, in the head and neck context) presents as metastatic squamous cell carcinoma in one or more cervical lymph nodes where an exhaustive search fails to identify the site of the primary tumor. It accounts for approximately 3–5% of all head and neck cancers. The occult primary is presumed to arise from the mucosal epithelium of the pharynx, oral cavity, or larynx — most frequently the oropharynx (base of tongue, tonsil) — but remains clinically and radiologically undetected. With the increasing prevalence of HPV-associated oropharyngeal cancer, a growing proportion of occult primary neck cancers are HPV-related (p16-positive), affecting younger non-smoking patients and carrying a significantly better prognosis than HPV-negative, tobacco-related cases. Modern investigative techniques including PET-CT, transoral robotic surgery (TORS), and narrow-band imaging endoscopy have substantially improved primary site detection rates, reducing the number of true occult primaries. Management requires close multidisciplinary collaboration.

The etiology of squamous cell carcinoma with occult primary is essentially the same as for known head and neck squamous cell carcinoma. HPV-16 infection is the dominant etiological factor in the increasing proportion of p16-positive cases, particularly in younger, non-smoking patients in Western countries. HPV-related occult primaries most commonly originate in the oropharynx (tonsillar crypts and base of tongue), where small HPV-infected lesions can produce large nodal metastases disproportionate to tumor size. Tobacco smoking — particularly combined with heavy alcohol consumption — remains the dominant risk factor for HPV-negative squamous cell carcinomas. EBV infection is the etiological driver for nasopharyngeal carcinoma metastases presenting as neck nodes. Additional risk factors include prior head and neck radiation, betel quid chewing (South and Southeast Asia), and occupational exposures to wood dust (sinonasal carcinoma). The term 'occult' reflects diagnostic rather than biological reality — the primary exists but is small enough or anatomically located such that it evades detection despite thorough investigation.

The typical presentation is a painless, progressively enlarging neck mass — usually in the upper or middle jugular lymph node chain (levels II and III) — in an adult without obvious mucosal head and neck symptoms. The mass is often hard, fixed, and may be discovered incidentally by the patient or found on routine examination. In HPV-positive occult primary cases, patients are typically male, in their 40s–50s, non-smokers, and may report recent mild throat discomfort or foreign body sensation. In HPV-negative cases, patients are more often older with significant tobacco and alcohol history; they may report weight loss, dysphagia, or odynophagia suggesting a mucosal primary site. Bilateral or lower cervical neck disease raises suspicion for a subglottic, thyroid, or infraclavicular primary. Skin involvement or rapid tumor growth suggests aggressive biology. Constitutional symptoms — weight loss, night sweats, fatigue — may accompany advanced disease. The key diagnostic challenge is distinguishing squamous cell carcinoma metastasis from lymphoma, thyroid cancer, and other neck mass etiologies.

A systematic and exhaustive investigative approach is essential. Fine needle aspiration cytology (FNAC) of the neck mass provides initial tissue diagnosis; open biopsy is avoided (may compromise surgical planning) unless FNAC is non-diagnostic after multiple passes. Core needle biopsy under ultrasound guidance improves yield. Histopathology confirms squamous cell carcinoma; p16 immunohistochemistry (surrogate for HPV) is mandatory and informs prognosis and treatment. EBV in situ hybridization (EBER-ISH) or EBV PCR is performed to identify nasopharyngeal carcinoma. CT of neck with contrast characterizes nodal staging (AJCC 8th edition N-staging). PET-CT is the most sensitive single imaging study for detecting the occult primary, identifying it in approximately 25–40% of cases after prior CT/MRI. MRI of pharynx and skull base provides complementary soft tissue detail. Direct laryngoscopy and endoscopy under anesthesia with systematic biopsies of the nasopharynx, base of tongue, tonsillar fossae (bilateral tonsillectomy), and piriform sinuses is recommended. TORS (transoral robotic surgery) for lingual tonsillectomy substantially increases primary site detection (detecting it in 60–80% of p16+ cases). Narrow-band imaging (NBI) endoscopy identifies mucosal abnormalities. If PET-CT and TORS are negative, the case is classified as true occult primary.

Treatment is guided by HPV/p16 status, N-stage, and whether a primary site is identified during workup. If a primary site is found after TORS or deep tonsillectomy, treatment proceeds as for known oropharyngeal carcinoma — transoral surgery ± adjuvant radiotherapy or chemoradiation, or definitive concurrent cisplatin-based chemoradiation (70 Gy in 35 fractions), with comprehensive nodal management via neck dissection or elective nodal irradiation. For true occult primary after exhaustive workup, the standard approach includes neck dissection (levels I–V ipsilateral for unilateral disease) followed by bilateral mucosal (pharyngeal axis) and ipsilateral neck irradiation. Comprehensive prophylactic irradiation targeting potential mucosal primary sites (bilateral oropharynx, nasopharynx, hypopharynx) at 50–56 Gy reduces mucosal recurrence but increases toxicity. NCCN guidelines recommend concurrent cisplatin (100 mg/m² q3-weekly or weekly) during radiation for N2–N3 disease. p16-positive patients have significantly better 5-year overall survival (>85% for N1 disease) than p16-negative patients (~40–60%). Radiation field de-intensification trials are ongoing for favorable HPV-positive cases. Immunotherapy (pembrolizumab) is approved for recurrent/metastatic disease.

The prognosis of squamous cell carcinoma of the neck with occult primary depends critically on HPV/p16 status and nodal stage. HPV-positive (p16-positive) disease — which now accounts for the majority of occult primary neck squamous cell carcinomas in Western countries — carries an excellent prognosis, with 5-year overall survival exceeding 85% for N1–N2 disease treated with standard cisplatin-based chemoradiation, outcomes comparable to known HPV-positive oropharyngeal primaries. De-escalation clinical trials (ECOG 3311, PATHOS, HN002) are actively evaluating whether treatment intensity can be safely reduced in favorable HPV-positive cases without compromising these outstanding outcomes. HPV-negative (p16-negative) occult primary squamous cell carcinoma has considerably worse prognosis, with 5-year overall survival of approximately 40–60% for N2–N3 disease treated with comprehensive chemoradiation and neck dissection. N-stage is the most important individual prognostic factor — N3 disease, bilateral nodal involvement, and extranodal extension reduce survival substantially across both HPV-positive and HPV-negative groups. Failure to identify the primary tumor site does not adversely affect survival when comprehensive prophylactic mucosal irradiation and adequate neck management are provided. Long-term functional sequelae of treatment — xerostomia, dysphagia, hypothyroidism, trismus, and neck fibrosis from radiation — are important considerations in long-term survivorship planning and rehabilitation. Recurrent or metastatic disease is managed with pembrolizumab-based immunotherapy per KEYNOTE-048 trial evidence, with durable responses achievable in some patients with PD-L1-positive tumors.

Prevention mirrors that of known head and neck squamous cell carcinoma. HPV vaccination (Gardasil 9 targeting HPV-16/18) is the most impactful preventive measure for HPV-related oropharyngeal and occult primary squamous cell carcinomas — most effective when administered before sexual debut; recommended up to age 26 routinely, and by shared decision up to age 45. Complete tobacco cessation and alcohol abstinence substantially reduce risk for HPV-negative squamous cell carcinomas. Routine oral cancer screening by dentists and primary care physicians can detect mucosal abnormalities early. HPV-related head and neck cancer is not transmitted by casual contact and patients should receive appropriate counseling. There is no established screening programme for head and neck cancer in the general population. Regular dental examinations with oral mucosal inspection provide an opportunity for early detection.

Any adult with a painless neck mass persisting more than two to three weeks requires urgent referral to a head and neck specialist — this presentation may represent metastatic squamous cell carcinoma with an occult primary, lymphoma, or other serious pathology. Do not attribute a new neck lump to 'glandular fever' or 'infection' without investigation if it persists beyond three weeks. A young non-smoking adult with a unilateral neck mass and no evidence of infection should be evaluated for HPV-related oropharyngeal or occult primary cancer. Prior to any excision biopsy of a neck mass in an adult, FNAC should be performed to exclude carcinoma — open biopsy of a neck mass without prior tissue diagnosis risks compromising subsequent surgical options. Patients with known HPV-positive head and neck cancer or prior tobacco and alcohol exposure who develop a new neck mass need urgent evaluation. Unexplained weight loss with neck mass warrants expedited investigation.